Hormonal and Metabolite Regulation of Hepatic Glucokinase.

Annu Rev Nutr

Institutes of Cellular Medicine and Ageing and Health, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH United Kingdom; email:

Published: July 2016

Liver glucose metabolism is dependent on glucokinase activity. Glucokinase expression is transcriptionally regulated by hormones and metabolites of glucose, and glucokinase activity is dependent on reversible binding of glucokinase to a specific inhibitor protein, glucokinase regulatory protein (GKRP), and to other binding proteins such as 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFK2/FBP2), which functions as an activator. Glucokinase is inhibited in the postabsorptive state by sequestration in the nucleus bound to GKRP, and it is activated postprandially by portal hyperglycemia and fructose through dissociation from GKRP, translocation to the cytoplasm, and binding to PFK2/FBP2. Glucagon dissociates this interaction, promoting translocation back to the nucleus. In humans, changes in glucokinase expression and activity are associated with poorly controlled type 2 diabetes and with nonalcoholic fatty liver disease, and a common variant of GKRP with altered binding affinity for glucokinase is associated with increased blood and liver lipids and other metabolic traits that implicate a role for GKRP in maintaining intrahepatic metabolite homeostasis.

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-nutr-071715-051145DOI Listing

Publication Analysis

Top Keywords

glucokinase
9
glucokinase activity
8
glucokinase expression
8
gkrp
5
hormonal metabolite
4
metabolite regulation
4
regulation hepatic
4
hepatic glucokinase
4
glucokinase liver
4
liver glucose
4

Similar Publications

Background: There is still no conclusive understanding of whether the glucokinase regulator (GCKR) gene rs780094 and rs1260326 polymorphisms predispose to gestational diabetes mellitus (GDM).

Objective: This systematic review and meta-analysis aimed to determine the effect of the GCKR polymorphisms on GDM susceptibility.

Methods: Seven literature databases were searched (from inception to February 17, 2024) to locate relevant studies included in further meta-analysis.

View Article and Find Full Text PDF

Introduction: A variety of hypoglycaemic drugs are used to treat polycystic ovarian syndrome (PCOS), but their efficacy remains insufficient. Glucokinase activators (GKAs) are a unique class of hypoglycaemic medications with emerging potential, notably in significantly reducing insulin resistance (IR). Nevertheless, the efficacy of GKAs in treating PCOS, particularly in the absence or presence of IR, remains uncertain.

View Article and Find Full Text PDF

Unlabelled: Globally, there is an increase in the prevalence of metabolic illnesses, including diabetes mellitus. However, current therapies for diabetes and other metabolic illnesses are not well understood. Pharmacological treatment of type 2 diabetes is challenging, moreover, the majority of antidiabetic medications are incompatible with individuals who have cardiac disease, renal illness, or liver damage.

View Article and Find Full Text PDF

Colitis, an inflammatory condition of the colon that encompasses ulcerative colitis (UC) and Crohn's disease, presents significant challenges due to the limitations and side effects of current treatments. This study investigates the potential of natural products, specifically AH and NSO, as organic therapeutic agents for colitis. Molecular docking studies were conducted to identify the binding affinities and interaction mechanisms between the bioactive compounds in AH and NSO and proteins implicated in colitis, such as those involved in inflammation and oxidative stress pathways.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!